Ahead of the long holiday weekend I thought this would be as good a time as any to once again go through the "Pharma's Market" mailbag. A couple of blog readers complained about my "short" story about Amgen.   Read More

What are the best plays when the market enters bear territory?   Read More

As much as I tried to disconnect during my vacation last week, I couldn't escape the ubiquitous presence of pharmaceuticals in our everyday lives...   Read More

Following are the week’s biggest winners and losers. Find out why shares of Goldman Sachs and Wyeth popped while Coca-Cola and Denny’s dropped.   Read More

The stock market ends the week in negative territory with all major indexes down almost 2% or greater, led by the Dow which dropped almost 4% for the week and broke the 12,000 level for the first time since March.   Read More

On Tuesday we received word of three exciting medical advancements. Find out what’s happening and how to trade them.   Read More

While numbers were lower for many units compared to the second quarter of last year, there was a clear improvement from the last quarter. For example, Investment Banking was 2 percent lower than the second quarter of 2007, but 44 percent higher than the first quarter of 2008.   Read More

It never ceases to amaze me who reads Pharma's Market. Like the Stanford University professor who wrote to set the record straight regarding my coverage from ASCO of the brain cancer vaccine from Pfizer and Avant.    Read More

I'm at the Needham & Company biotech conference in New York City. Whenever possible I like to attend events like this. It's a good place to get story ideas. The Needham meeting is competing this year with a similar one being put on by Goldman Sachs in Laguna Beach, CA.    Read More

Cancer, diabetes and Alzheimer's Disease. Three of the biggest areas of unmet medical need have been or will be in focus at a series of important scientific meetings in June or July.    Read More